Retatrutide (Chinese-made)

Retatrutide (LY3437943) is a revolutionary triple agonist peptide that can simultaneously activate three metabolic hormone receptors: GLP-1 (glucagon like peptide-1), GIP (glucose dependent insulinotropic polypeptide), and glucagon receptor. This pioneering triple mechanism represents the most advanced method in metabolic peptide research. Compared with dual GIP/GLP-1 agonists, the addition of glucagon receptor agonists significantly enhanced energy expenditure and hepatic lipid oxidation. In the second trial published in the New England Journal of Medicine (2023), participants who received Rituotide achieved an unprecedented average weight loss of 24.2% at 48 weeks, the highest reported weight loss effect among all anti obesity drugs. The glucagon component also uniquely drives thermogenesis and hepatic lipid clearance, with some study participants showing complete disappearance of hepatic steatosis.